Tuesday, June 28, 2016 | 8:00 AM - 5:30 PM
Keynote Speaker: Giancarlo Comi (Università Vita-Salute San Raffaele)
Explore novel and emerging treatments for multiple sclerosis, including biomarkers and MRI usage in disease diagnosis, prognosis, and monitoring.
Wednesday, July 13, 2016 | 9:00 AM - 5:00 PM
Keynote Speaker: David Bartel (Whitehead/MIT/HHMI)
Speakers: Paul Grint (Regulus Therapeutics), David S Hong (The University of Texas MD Anderson Cancer Center ), Daniel J Siegwart (University of Texas Southwestern Medical Center), Frank Slack (BIDMC Cancer Center/Harvard Medical School), James W Welsh (The University of Texas MD Anderson Cancer Center)
miRNAs play critical roles in regulating gene expression. This symposium will present up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.
Thursday, September 8, 2016 | 9:00 AM - 5:00 PM
Speakers: Hans-Joachim Anders (Klinikum der Universität München), Caroline Fox (Merck Research Labs), John Cijiang He (The Mount Sinai Medical Center), Matthias Kretzler (University of Michigan), Kevin V Lemley (University of Southern California), Roger C. Wiggins (University of Michigan), Jochen Reiser (RUSH University), and Katalin Susztak (Perelman School of Medicine)
Accumulating evidence supports a role for renal inflammation and podocytopathy in pathogenesis and progression of chronic kidney disease. This symposium will delve into the mechanisms underlying this pathology.
Friday, October 7, 2016 | 9:00 AM - 5:00 PM
Mental illness causes debilitating consequences on quality of life for individuals, families, and society. This symposium explores avenues for translating these discoveries about the neurobiology of a spectrum of mental illnesses into new treatments.
Tuesday, October 25, 2016 | 9:00 AM - 5:00 PM
Speakers: Marcus Bantscheff (Cellzome/GSK), Benjamin F Cravatt (The Scripps Research Institute), Craig Crews (Yale University), Howard Hang (The Rockefeller University), Ruth Nussinov (National Cancer Institute), Brian Raymer (Pfizer), Bryan Roth (University of North Carolina), Eranthie Weerapana (Boston College)
Chemical Biology is changing the face of drug discovery. This symposium will highlight recent developments in the field, featuring examples from neurobiology and cancer, the ubiquitin proteasome system, GPCRs, and protein lipidation.
Tuesday, June 21, 2016 | 8:30 AM - 5:00 PM
Keynote Speaker: Sharon Inouye (Harvard Medical School)
This meeting will convene leading scientists and physicians to discuss the challenges and opportunities to create biomarkers and therapeutics for these patients who are vulnerable to delirium, cognitive decline, and dementia following surgery.
Monday, June 13, 2016 | 10:00 AM - 3:30 PM
Speakers: Ruslan M. Medzhitov (Yale School of Medicine, Howard Hughes Medical Institute), Mauro Perretti (The William Harvey Research Institute, Queen Mary University of London), Charles N. Serhan (Brigham and Women's Hospital & Harvard Medical School), Lars Klareskog (Karolinska Institutet), and Kevin J. Tracey (The Feinstein Institute for Medical Research)
This symposium will honor Dr. Charles N. Serhan, the recipient of the 2016 Ross Prize in Molecular Medicine, for his important discoveries in identifying bioactive mediators and cellular pathways critical in the resolution of inflammatory diseases.
Wednesday, May 25, 2016 | 11:30 AM - 5:00 PM
Speakers: Philip A. Cole (Johns Hopkins University School of Medicine), Kenneth W. Duncan (Epizyme, Inc.)
The Chemical Biology Discussion Group brings together chemists and biologists interested in discussing the latest breakthroughs. In 2016, the annual year-end meeting features keynote speakers Dr Philip Cole and Dr Kenneth Duncan.
Thursday, April 28, 2016 | 9:00 AM - 5:00 PM
Keynote Speaker: Craig B. Thompson (Memorial Sloan Kettering Cancer Center)
Speakers: Michael Elowitz (California Institute of Technology), Eric Campeau (Zenith Epigenetics), Ewelina Kulikowski (Resverlogix Corp), Keiko Ozato (National Institute of Child Health and Human Development), Roberto Pili (Indiana University School of Medicine), Patrick Trojer (Constellation), Christopher Vakoc (Cold Spring Harbor Laboratory), Daniel Vitt (4SC AG)
Epigenetic abnormalities are a recognized contributing factor in tumorigenesis and other diseases. This symposium describes recent progress in validating the therapeutic potential of small molecule inhibitors targeting epigenetics marks.
Organizers: Renier Brentjens (Memorial Sloan Kettering Cancer Center), George Zavoico (Jones Trading Institutional Services), Sonya Dougal (The New York Academy of Sciences), and Caitlin McOmish (The New York Academy of Sciences)
This eBriefing explores advances in cancer immunotherapy, which engages the immune system to detect and destroy cancer cells and has gained popularity and success in recent years.
Edited by Annals of the New York Academy of Sciences
Recent discoveries in lysosome biology and the therapeutic potential of drugs targeting the lysosome in various diseases.
Organizers: Jane S. Lebkowski (Asterias Biotherapeutics), George Zavoico (JonesTrading Institutional Services), Sonya Dougal (The New York Academy of Sciences), and Caitlin McOmish (The New York Academy of Sciences)
This eBriefing considers efforts to rethink clinical, regulatory, and manufacturing approaches to accelerate the transition of cell-based therapies to the clinic.
Edited by Daniel H. Geschwind
(University of California, Los Angeles)
Scholarly commissioned review articles on topics spanning neurology and psychiatry